Allakos Inc (ALLK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Allakos Inc (ALLK) has a cash flow conversion efficiency ratio of -0.511x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.36 Million) by net assets ($55.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Allakos Inc (ALLK) total market value for the company's overall valuation and market capitalisation.
Allakos Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Allakos Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Allakos Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Allakos Inc ranked by their cash flow conversion efficiency. Explore ALLK operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
P-Two Industries
TWO:6158
|
0.098x |
|
Symphony Life Bhd
KLSE:1538
|
-0.004x |
|
MUI Properties Bhd
KLSE:3913
|
0.757x |
|
The Navakij Insurance Public Company Limited
BK:NKI
|
-0.087x |
|
Ledtech Electronics Corp
TW:6164
|
0.027x |
|
Sung Bo Chem
KO:003080
|
-0.044x |
|
Numulae Gestion de Servicios SOCIMI SA
MC:YNUM
|
-0.001x |
|
Coreana Cosmetics Co.Ltd
KQ:027050
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Allakos Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Allakos Inc from 2016 to 2024. View ALLK stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $78.82 Million | $-93.62 Million | -1.188x | -72.16% |
| 2023-12-31 | $168.82 Million | $-116.48 Million | -0.690x | +23.49% |
| 2022-12-31 | $310.43 Million | $-279.97 Million | -0.902x | -93.29% |
| 2021-12-31 | $445.48 Million | $-207.85 Million | -0.467x | -168.01% |
| 2020-12-31 | $654.39 Million | $-113.92 Million | -0.174x | -36.96% |
| 2019-12-31 | $495.72 Million | $-63.01 Million | -0.127x | +39.17% |
| 2018-12-31 | $183.99 Million | $-38.45 Million | -0.209x | -154.42% |
| 2017-12-31 | $-58.77 Million | $-22.57 Million | 0.384x | -20.40% |
| 2016-12-31 | $-36.44 Million | $-17.58 Million | 0.482x | -- |
About Allakos Inc
As of May 15, 2025, operates as a subsidiary of Concentra Biosciences, LLC.